This is a news story, published by CNBC, that relates primarily to Novo Nordisk's Ozempic news.
For more drug discoveries news, you can click here:
more drug discoveries newsFor more news from CNBC, you can click here:
more news from CNBCOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
blockbuster diabetes drug Ozempic. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest opioid epidemic news, other diabetes medications news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
ongoing opioid epidemicCNBC
•
88% Informative
The active ingredient in Novo Nordisk's Ozempic , semaglutide, was associated with a "significantly lower" opioid overdose risk than other diabetes medications.
The study adds to growing evidence that a class of diabetes and obesity treatments called GLP-1s may have health benefits beyond regulating blood sugar and promoting weight loss.
There are currently three effective medications to prevent overdoses from opioid use disorder.
VR Score
91
Informative language
94
Neutral language
48
Article tone
formal
Language
English
Language complexity
74
Offensive language
likely offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
5
Source diversity
5
Affiliate links
no affiliate links